Research Analysts Set Expectations for IRWD Q1 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Ironwood Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings per share of ($0.06) for the quarter, down from their previous estimate of $0.03. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals' Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.08 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $91.60 million for the quarter, compared to analysts' expectations of $91.22 million. During the same period in the previous year, the firm earned $0.12 earnings per share. The firm's revenue for the quarter was down 19.4% on a year-over-year basis.

IRWD has been the subject of several other research reports. JMP Securities cut their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a report on Thursday, January 30th. Craig Hallum cut their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.67.

Ironwood Pharmaceuticals Trading Down 8.1 %

NASDAQ:IRWD traded down $0.17 during trading hours on Monday, reaching $1.94. The company had a trading volume of 9,311,548 shares, compared to its average volume of 2,676,335. The firm has a market cap of $310.46 million, a price-to-earnings ratio of -64.67 and a beta of 0.29. The firm's 50 day moving average price is $3.77 and its 200-day moving average price is $4.34. Ironwood Pharmaceuticals has a 52 week low of $1.89 and a 52 week high of $15.70.

Insider Activity

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the company's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.90% of the company's stock.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Pacer Advisors Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after purchasing an additional 450,949 shares during the last quarter. State Street Corp increased its stake in Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock worth $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company's stock worth $7,846,000 after acquiring an additional 364,841 shares in the last quarter. FMR LLC boosted its position in shares of Ironwood Pharmaceuticals by 25.1% during the 3rd quarter. FMR LLC now owns 169,681 shares of the biotechnology company's stock valued at $699,000 after acquiring an additional 34,089 shares during the last quarter. Finally, Weiss Asset Management LP purchased a new position in shares of Ironwood Pharmaceuticals in the third quarter valued at $893,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.